Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01403064
Recruitment Status : Terminated (due to lack of efficacy)
First Posted : July 27, 2011
Last Update Posted : April 24, 2018
Information provided by (Responsible Party):
Vitaeris INC

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy

Condition or disease Intervention/treatment Phase
Oral Mucositis Biological: ALD518 Drug: 0.9% saline Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy
Study Start Date : July 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Open Label ALD518 Biological: ALD518
Experimental: ALD518 Dose 1 Biological: ALD518
Experimental: ALD518 Dose 2 Biological: ALD518
Placebo Comparator: Placebo Drug: 0.9% saline
IV Infusion

Primary Outcome Measures :
  1. Safety and tolerability of ALD518, including incidence of adverse events, serious adverse events and clinically significant laboratory abnormalities [ Time Frame: Participants will be followed for the duration of the trial, an expected average of 12 months ]
  2. Clinically assessed ulcerative OM (Who Grade ≥ 2) at a cumulative radiation dose of 55 Gy [ Time Frame: The average time of this assessment will be 5-7 weeks after the initiation of RT ]

Secondary Outcome Measures :
  1. Secondary efficacy endpoint of OM assessments [ Time Frame: Measured from onset of OM through Week 4 Post-RT ]
    Ulcerative (WHO Grade ≥ 2) and severe (WHO Grade ≥ 3) OM at cumulative doses of 35 Gy, 45 Gy, 55 Gy and 65 Gy; Duration of ulcerative and severe OM, Time of onset of ulcerative and severe OM

  2. Pharmacokinetics of ALD518 in plasma [ Time Frame: Measured at Baseline, Week 2, Week 4, Last Day of RT and Week 4 Post-RT ]
  3. Impact of ALD518 on Patient-reported Outcomes as measured by the OMDQ, FACT-HN, and FACIT-fatigue scale [ Time Frame: Begins at baseline and is measured at least weekly though WEek 4 Post-RT ]
  4. C-reactive protein serum concentrations [ Time Frame: Measured at intervals from Screening visit through Week 4 Post-RT ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have recently diagnosed (< than 6 months prior to screening visit date), pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as first-line treatment; subjects with a history of surgical management (approximately 4-6 weeks before RT with sufficient time for post-surgical healing) are eligible
  • Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy.
  • Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2)
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • CRP < 80 mg/L
  • Have adequate hematopoietic, hepatic, and renal function at the screening visit

Exclusion Criteria:

  • Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor
  • Metastatic disease (M1) Stage IV C
  • Any prior history of head and neck cancer
  • Prior radiation to the head and neck
  • Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial
  • Active infectious disease, excluding oral candidiasis
  • Have OM at the screening visit
  • Have a history of hypersensitivity to monoclonal antibody

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01403064

  Hide Study Locations
United States, Florida
Morton Plant Mease Health Care
Clearwater, Florida, United States, 33756
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Center
Detroit, Michigan, United States, 48201
Detroit Clinical Research Center
Farmington Hills, Michigan, United States, 48336
United States, New Jersey
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New Mexico
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87106
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
SUNY Upstate Medical University
Syracuse, New York, United States, 13210
United States, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
Spartanburg Regional Medical Center
Spartanburg, South Carolina, United States, 29303
United States, Texas
Cancer Specialists of Southern Texas
Corpus Christi, Texas, United States, 78412
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
United States, Washington
VA Puget Sound Health Care Syatem
Seattle, Washington, United States, 98108
Australia, New South Wales
St. Vincent's Hospital
Darlinghurst, New South Wales, Australia, 2010
Calvary Mater Newcastle
Waratah, New South Wales, Australia, 2298
Australia, Queensland
Royale Brisbane and Women's Hospital
Herston, Queensland, Australia, 4029
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Australia, South Australia
Adelaide Radiotherapy Centre
Adelaide, South Australia, Australia, 5037
Royal Adelaide Hospital
Adelaide, South Australia, Australia
LKH Graz, HNO Ambulanz
Graz, Austria
Univ. Klinik fur Innere Medizin III
Salzburg, Austria, 5020
Hanusch Krankenhaus
Vienna, Austria, 1140
Canada, Ontario
Cancer Centre of Southeastern Ontario
Kingston, Ontario, Canada, K7L 5P9
Canada, Quebec
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4
CHUQ-L'Hotel-Dieu de Quebec
Quebec, Canada, G1R 2J6
Universitatsklinikum Freiburg
Freiburg, Germany, 79106
University Medical School, Saarland
Homburg, Germany, 66424
Uniklinik Koln
Koln, Germany, 50924
A.O. San Paolo - Polo Universitario
Milan, Italy, 20142
Istituto Nazionale dei tumari
Milan, Italy
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
Udine, Italy, 33100
Sponsors and Collaborators
Vitaeris INC
Study Director: Jeffrey Smith, MD FRCP Alder Biopharmaceuticals, Inc.

Responsible Party: Vitaeris INC Identifier: NCT01403064     History of Changes
Other Study ID Numbers: ALD518-CLIN-009
First Posted: July 27, 2011    Key Record Dates
Last Update Posted: April 24, 2018
Last Verified: April 2018

Keywords provided by Vitaeris INC:
Oral mucositis; head and neck cancer; chemotherapy; radiotherapy

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases